B
Bruce E. Miller
Researcher at GlaxoSmithKline
Publications - 119
Citations - 12045
Bruce E. Miller is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: COPD & Exacerbation. The author has an hindex of 45, co-authored 119 publications receiving 10318 citations. Previous affiliations of Bruce E. Miller include Duke University & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
John R. Hurst,Jørgen Vestbo,Jørgen Vestbo,Antonio Anzueto,Nicholas Locantore,Hana Müllerová,Ruth Tal-Singer,Bruce E. Miller,David A. Lomas,Alvar Agusti,William MacNee,Peter M.A. Calverley,Stephen I. Rennard,Emiel F.M. Wouters,Jadwiga A. Wedzicha +14 more
TL;DR: Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.
Journal ArticleDOI
Characterisation of COPD heterogeneity in the ECLIPSE cohort
Alvar Agusti,Peter M.A. Calverley,Bartolome R. Celli,Harvey O. Coxson,Lisa D. Edwards,David A. Lomas,William MacNee,Bruce E. Miller,S.I. Rennard,Edwin K. Silverman,Ruth Tal-Singer,Emiel F.M. Wouters,Julie C. Yates,Jørgen Vestbo +13 more
TL;DR: The clinical manifestations of COPD are highly variable and the degree of airflow limitation does not capture the heterogeneity of the disease.
Journal ArticleDOI
Changes in forced expiratory volume in 1 second over time in copd
Jørgen Vestbo,Jørgen Vestbo,Lisa D. Edwards,Paul D. Scanlon,Julie C. Yates,Alvar Agusti,Per Bakke,Peter M.A. Calverley,Bartolome R. Celli,Harvey O. Coxson,Courtney Crim,David A. Lomas,William MacNee,Bruce E. Miller,Edwin K. Silverman,Ruth Tal-Singer,Emiel F.M. Wouters,Stephen I. Rennard +17 more
TL;DR: The rate of change in FEV(1) among patients with COPD is highly variable, with increased rates of decline among current smokers, patients with bronchodilator reversibility, and patients with emphysema.
Journal ArticleDOI
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype.
Alvar Agusti,Lisa D. Edwards,Stephen I. Rennard,William MacNee,Ruth Tal-Singer,Bruce E. Miller,Jørgen Vestbo,Jørgen Vestbo,David A. Lomas,Peter M.A. Calverley,Emiel F.M. Wouters,Courtney Crim,Julie C. Yates,Edwin K. Silverman,Harvey O. Coxson,Per Bakke,Ruth J. Mayer,Bartolome R. Celli +17 more
TL;DR: Overall, the results identify a novel systemic inflammatory COPD phenotype that may be the target of specific research and treatment and show associations but do not prove causality.
Journal ArticleDOI
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study
Kenneth B. Gordon,Richard G. Langley,Craig L. Leonardi,Darryl Toth,M. Alan Menter,Sewon Kang,Michael P. Heffernan,Bruce E. Miller,Regina Hamlin,Liberata Lim,Jianhua Zhong,Rebecca S. Hoffman,Martin M. Okun +12 more
TL;DR: Adalimumab significantly improved psoriasis and was well tolerated for 60 weeks and was insufficiently powered to detect rare adverse events associated with adalimumAB.